



Endurance sport and atrial fibrillation: a mini-review of a complex relationship

Marcello Costantini^{1*} , Marcelo Victor Elizari², Mario Previtali³, Luigi Sciarra⁴ , Franco Luzzza⁵, Lorenzo Costantini⁶, Vincenzo Carbone⁷, Michele Maffia⁸

¹DREAM, Laboratorio diffuso di ricerca interdisciplinare applicata alla Medicina, ASL Lecce-Università del Salento, 73100 Lecce, Italy

²Academia Nacional de Medicina, Buenos Aires C1221ADC, Argentina

³Istituto Clinico Città di Pavia, Gruppo San Donato, 27100 Pavia, Italy

⁴Department of Cardiovascular Disease, University of L'Aquila, 67100 L'Aquila, Italy

⁵Malattie Apparato Cardiovascolare, Università degli Studi, 98100 Messina, Italy

⁶Cardionair-Research in Telecardiology Center, 73048 Nardò, Italy

⁷Cardiologia Ambulatoriale, ASL Napoli 3 sud e Salerno, 73100 Lecce, Italy

⁸DREAM, Istituto di Fisiologia, University of Salento, 73100 Lecce, Italy

***Correspondence:** Marcello Costantini, DREAM, Laboratorio diffuso di ricerca interdisciplinare applicata alla Medicina, ASL Lecce-Università del Salento, 73100 Lecce, Italy. marcellocostantini9@gmail.com

Academic Editor: Hassane Zouhal, Rennes 2 University, France

Received: February 13, 2025 **Accepted:** April 14, 2025 **Published:** July 30, 2025

Cite this article: Costantini M, Elizari MV, Previtali M, Sciarra L, Luzzza F, Costantini L, et al. Endurance sport and atrial fibrillation: a mini-review of a complex relationship. *Explor Cardiol.* 2025;3:101267. <https://doi.org/10.37349/ec.2025.101267>

Abstract

Scientific evidence seems to indicate that, in males, intense and prolonged endurance sport can favor the onset of atrial fibrillation. A plausible explanation may be the impact that intense endurance sports produce on the three vertices of Coumel's triangle. However, genetics is probably also involved in translating this impact into an arrhythmic phenotype. On a management level, the first task of the cardiologist is to exclude the presence of structural heart disease, channelopathy, endocrine and/or electrolyte disorders, and substance use. As for the treatment of arrhythmia, the "CARE" paradigm proposed by the latest ESC guidelines should probably be accompanied by detraining, although this suggestion is often rejected by the athlete. Anticoagulant therapy, where indicated, must take into account the risk of trauma that the sport entails, even if the particular pharmacodynamics/pharmacokinetics of DOACs should allow training/competition to take place when the anticoagulant effect of the previous administration has completely or almost completely worn off.

Keywords

Atrial fibrillation, endurance sport, Coumel's triangle



Introduction

Hypothesizing an etiological relationship between sport and atrial fibrillation (AF) may seem paradoxical, since strong evidence indicates that, in addition to bringing a significant reduction in cardiovascular risk factors and all-cause mortality [1], physical activity is a cornerstone of both primary and secondary prevention of AF [2–4]. Physical activity is even considered an integral part of treatment in subjects with permanent AF, since it assists in rate control, improves quality of life, reduces thrombogenesis, improves endothelial function, and promotes positive atrial remodeling [5, 6]. Yet, it should be noted that a substantial number of works appearing in the literature have associated endurance sports, characterized by isotonic-dynamic muscular activity, predominantly powered by aerobic energy (e.g., marathon running, cross-country skiing, cycling, swimming) with the risk of AF, and this has raised doubts about the real benefits of endurance with respect to the prevention of arrhythmia.

Available data

Studies by Karjalainen et al. [7], Mont et al. [8], Molina et al. [9], Elosua et al. [10], Heidbüchel et al. [11], and Baldesberger et al. [12] unanimously report that endurance sports can favor the onset of AF in middle-aged people. However, many of these studies have attracted criticism over the small number of subjects, because they were mostly retrospective, or because they were flawed by questionable enrollment criteria [13]; not to mention the fact that other studies [2, 14–16] have yielded opposite results. Evidence from subsequent important studies substantially supported the observation that intense physical activity could, in fact, act as a risk factor for AF. These include an American study based on data from the Physician Health Study, which enrolled approximately 17,000 males. The results showed a correlation between the dose of physical exercise and the incidence of AF [17]. In another study, Calvo et al. [18] demonstrated that the incidence of lone AF is higher in athletes with an intense endurance curriculum exceeding 2,000 hours. A Swedish study that enrolled 1.1 million male subjects, following them for approximately 26 years, demonstrated a U-shaped trend in the risk of AF as the level of physical activity increased [19]. A meta-analysis by Newman et al. [20] showed that in athletes and non-athletes without cardiovascular disease risk factors (i.e., diabetes mellitus and hypertension), athletes had a significantly greater relative risk of AF and that younger athletes (< 55 years) had a significantly higher relative risk of AF than older athletes. Another meta-analysis by Ayinde et al. [21] confirmed that the risk of AF is significantly higher in younger athletes (< 54 years) than in older athletes. What is striking about these studies is that the subjects enrolled are almost always male. Surprisingly, studies [22, 23] and meta-analyses [24, 25] including equal numbers of men and women reveal completely opposite trends for the two sexes: the incidence of AF continues to decrease in females even when they perform intense physical activity. Accepted by the guidelines of various scientific societies [26, 27], these data are part of the many substantial arrhythmological differences between males and females (see Table 1).

Table 1. Arrhythmological differences between the two sexes

In females ↑	In males ↑
Basal sinus rate	Atrio-ventricular reentry tachycardia
Inappropriate sinus tachycardia	Atrial fibrillation in athletes
AV nodal re-entry tachycardia	Distal AV block
Aquired long QT syndrome	Sudden cardiac death
Torsade de pointes	
Ischemic stroke risk related to atrial fibrillation	
Sick sinus syndrome	

The most significant arrhythmological differences between the two sexes are reported. In females, the “basal” sinus frequency is generally higher than in males. Inappropriate sinus tachycardia is an arrhythmological condition almost exclusively of the female sex. In women, the incidence of AV nodal reentry tachycardia is higher than in men, as is the incidence of acquired long QT syndrome and—consequently—the risk of torsade de pointes. In women affected by atrial fibrillation, the risk of ischemic stroke is higher than in men. Finally, the incidence of sick sinus syndrome is higher in women than in men. In men, the incidence of atrioventricular reentry tachycardia involving an accessory pathway, atrial fibrillation in athletes, distal atrioventricular block, and sudden cardiac death is higher

Mechanisms involved

The higher incidence, shown in the data and accepted by the scientific community, of AF in males who practice intense endurance requires a scientifically plausible explanation. It is well documented that AF is an arrhythmia due to the chaotic multiple reentry of the impulse within the atrial musculature [28], propitiated by a critical level of interaction between a substrate (the atrial muscle mass) and by modulation of the same substrate by functional factors (vagus/sympathetic), in the presence of a trigger mechanism (generally represented by atrial ectopic beats, often starting from the pulmonary veins). AF, therefore, paradigmatically embodies Coumel's concept of the "arrhythmia triangle" [29], and it has been scientifically demonstrated that intense endurance sport consistently impacts all three vertices of this iconic triangle:

1) It impacts the substrate (atrial dilation, atrial fibrosis, inflammation, cellular damage, and electrical remodeling [30–32]).

2) It impacts the functional modulation of the same substrate (increased vagal activity at rest; increased sensitivity to acetylcholine; reduction of refractory periods of atrial cells; dispersion of atrial refractoriness, and increased sympathetic tone during exercise [4, 33]).

3) It impacts trigger factors (increased atrial ectopias; often other atrial arrhythmias can trigger AF [4, 33]).

It should also be considered that, according to recent studies, vigorous and prolonged endurance leads to an increase in the level of circulating microRNA [34]. As is known, microRNA is a regulator of gene expression and takes an active part in cellular differentiation, growth, and apoptosis [35], while from the cardiovascular point of view, it is closely involved in physiopathological processes such as hypertrophy, fibrosis, and myocellular damage [36]. Changes in microRNA levels, demonstrated in endurance athletes, can favor atrial fibrosis, making the substrate more favorable to the onset of AF [34].

Another recent acquisition that could be important in this context is the demonstrated presence of an electromechanical feedback cycle in the human heart, on the basis of which excitability, conduction and activity of membrane ion channels are influenced by the "mechanical environment" in which they are situated [37]. The medium of this feedback is the "mechano-gated ion channels", at the same time sensors of mechanical activity and effectors of electrical responses, by means of interactions with the ion channels responsible for the electrical activity of the membrane. The strong impact of intense physical activity on the "mechano-gated ion channels" can modulate proarrhythmic electrical feedback and thus favor the onset of AF [38].

Finally, the risk of AF related to endurance is probably modulated by genetic factors that interact in various ways with structural and electrical remodeling, more or less markedly favoring the onset of arrhythmia, as hypothesized by Fatkin et al. [39].

As for the rationale for the relationship between gender and different propensity to AF in subjects who practice intense endurance, the available studies highlight a difference in atrial remodeling, both chronic and acute, in the two sexes, which could perhaps provide a key to understanding. In male athletes, chronic left ventricular hypertrophy and diastolic dysfunction prevail; in female athletes, there is a different modality of acute remodeling, which reversibly impacts the right sections, while chronic left ventricular hypertrophy and diastolic dysfunction are less evident [40, 41].

Therapeutic management and eligibility for competitive sports

When faced with an athlete with AF, the first task of the doctor is to properly frame the subject from a cardiological point of view, excluding structural heart disease, channelopathies, thyroid disorders, alcohol abuse and use of performance-enhancing drugs. In the absence of dedicated studies, the therapeutic choices should refer to the current guidelines: those just published by the European Society of Cardiology [42] introduce the CARE paradigm as the basis of the approach to AF [C: comorbidity and risk factor treatment; A: avoid stroke; R: reduce symptoms (rate and rhythm control); E: evaluation and dynamic reassessment], which can also be a valuable guide here. However, there are some important peculiarities to take into consideration with patients who are athletes:

- 1) The treatment, whatever it is, must not significantly impact their physical performance.
- 2) The treatment must be well tolerated.
- 3) The treatment must be shared and accepted by the athlete.
- 4) Any drugs used must not be included in the list of “prohibited” substances (such as beta blockers in some sports).
- 5) If anticoagulant treatment is considered, the traumatic risk that the sport may entail must be considered.

But above all, a fifth letter must be added to the four letters of the CARE paradigm: the “D” of “detraining”. Experimental and human studies demonstrate that detraining alone can significantly reduce the incidence of AF in athletes who are affected by it [33, 43, 44]. A common clinical recommendation is to have the athlete with symptomatic AF reduce the duration and intensity of exercise for up to 3 months to assess the relationship of exercise to AF [33], but this approach is based solely on anecdotal evidence and expert opinions [33], and the first randomized controlled trial on this specific topic is still ongoing [45]. However, many athletes refuse detraining: a completely understandable attitude, which must be respected. In such cases, or when detraining does not produce significant results, the “R” of the CARE paradigm must be brought into play, with the patient being managed by controlling rate or rhythm. In the past, the choice between the two options represented a major dilemma for the cardiologist: today, the two strategies are seen as complementary and adopting one or the other is a decision that must always be re-evaluated in follow-up, as the recently published guidelines themselves indicate [42]. Of course, in athletes, rate control (leaving the arrhythmia to itself and simply controlling the ventricular rate) is an option that does not give satisfactory results [33, 41]: the drugs used for this purpose (beta blockers and non-dihydropyridine Ca-antagonists) are often not well tolerated, are sometimes prohibited (beta blockers), or are not very effective, while it is known that digitalis does not safely/effectively control the ventricular rate of AF in athletes [33, 41]. Rhythm control (trying to restore and maintain sinus rhythm) is not much better: class IC drugs are effective, but if the arrhythmia arises during a race or training, flecainide or propafenone can cause the AF to transform into atrial flutter, which can be conducted to the ventricles at a very rapid rate, even with 1:1 conduction, with emergency or catastrophic consequences [33, 41, 46]. In case of drug failure or as a first-line option in selected cases, there is catheter ablation, the results of which seem to be superimposable on those for the general population [46, 47]. With regard to antithrombotic prophylaxis, it seems obvious that, in the athlete, the risk assessed with CHA2DS2-VA is often zero, but the problem should not be underestimated, given that some evidence indicates a non-negligible incidence of stroke in senior athletes affected by AF [48, 49]. In the event that anticoagulant therapy is started, the attitude so far has been to prohibit contact sports or in any case sports with a traumatic risk [26, 33]. The particular pharmacodynamics and pharmacokinetics of direct-acting oral anticoagulants (DOAC) could perhaps introduce some innovations in this field: theoretically, the athlete could be allowed, by calibrating the time of administration of the DOAC [50, 51], to perform competitions/training limited to the period in which the effect of the drug is minimal or null.

The last but not least important question is precisely that of the eligibility for competitive sports of athletes with AF. A recent document submitted to the literature by an Italian expert committee states that in the absence of Wolff-Parkinson-White (WPW), eligibility should be granted under the following conditions [52]:

- Absence of heart disease incompatible with competitive sports and absence of major symptoms.
- Any identifiable triggering cause has been identified and removed.
- There is no cause-effect relationship between sports activities and arrhythmia.
- The AF episode is infrequent, is not high frequency and is of limited duration.

If AF is permanent, eligibility could be granted for low or moderate cardiovascular commitment sports activities, provided there is no heart disease or significant symptoms, and the heart rate during exercise test and electrocardiogram (ECG) monitoring does not exceed the maximum heart rate (HR) for the athlete's age [52]. Italian guidelines tend to be more specific and restrictive than European ones: the latter indicate good practice for subjects engaging in physical activity at various levels [53]. As has already been observed, athletes on anticoagulant therapy have so far been excluded from participating in sports activities with a high risk of trauma [52, 53].

Conclusions

In conclusion, intense endurance sports increase the risk of AF in males, especially in middle-aged ones. In the management of arrhythmia, the “D” of detraining is added to the CARE paradigm. The topic deserves further study to better define mechanisms, subjects at risk and management. Finally, we believe that generating doubts about the beneficial effect of physical activity can be somewhat dangerous and is not scientifically justified.

Abbreviations

AF: atrial fibrillation

DOAC: direct-acting oral anticoagulants

Declarations

Acknowledgments

We are grateful to Dr. Claire Archibald for her support and guidance.

Author contributions

MC: Conceptualization, Writing—original draft. MVE: Writing—review & editing. MP: Conceptualization, Writing—review & editing. LS: Writing—review & editing. LC: Writing—original draft. FL: Data curation, Writing—review & editing. VC: Writing—review & editing. MM: Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

© The Author(s) 2025.

Publisher's note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

1. Lavie CJ, Ozemek C, Carbone S, Katzmarzyk PT, Blair SN. Sedentary Behavior, Exercise, and Cardiovascular Health. *Circ Res*. 2019;124:799–815. [DOI] [PubMed]
2. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study. *Circulation*. 2008;118:800–7. [DOI] [PubMed] [PMC]
3. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, et al. Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese Individuals With Atrial Fibrillation: The CARDIO-FIT Study. *J Am Coll Cardiol*. 2015;66:985–96. [DOI] [PubMed]
4. Buckley BJR, Lip GYH, Thijssen DHJ. The counterintuitive role of exercise in the prevention and cause of atrial fibrillation. *Am J Physiol Heart Circ Physiol*. 2020;319:H1051–8. [DOI] [PubMed]
5. Reed JL, Mark AE, Reid RD, Pipe AL. The effects of chronic exercise training in individuals with permanent atrial fibrillation: a systematic review. *Can J Cardiol*. 2013;29:1721–8. [DOI] [PubMed]
6. Osbak PS, Mourier M, Kjaer A, Henriksen JH, Kofoed KF, Jensen GB. A randomized study of the effects of exercise training on patients with atrial fibrillation. *Am Heart J*. 2011;162:1080–7. [DOI] [PubMed]
7. Karjalainen J, Kujala UM, Kaprio J, Sarna S, Viitasalo M. Lone atrial fibrillation in vigorously exercising middle aged men: case-control study. *BMJ*. 1998;316:1784–5. [DOI] [PubMed] [PMC]
8. Mont L, Sambola A, Brugada J, Vacca M, Marrugat J, Elosua R, et al. Long-lasting sport practice and lone atrial fibrillation. *Eur Heart J*. 2002;23:477–82. [DOI] [PubMed]
9. Molina L, Mont L, Marrugat J, Berrueto A, Brugada J, Bruguera J, et al. Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow-up study. *Europace*. 2008;10:618–23. [DOI] [PubMed]
10. Elosua R, Arquer A, Mont L, Sambola A, Molina L, García-Morán E, et al. Sport practice and the risk of lone atrial fibrillation: a case-control study. *Int J Cardiol*. 2006;108:332–7. [DOI] [PubMed]
11. Heidbüchel H, Anné W, Willems R, Adriaenssens B, Werf FVd, Ector H. Endurance sports is a risk factor for atrial fibrillation after ablation for atrial flutter. *Int J Cardiol*. 2006;107:67–72. [DOI] [PubMed]
12. Baldesberger S, Bauersfeld U, Candinas R, Seifert B, Zuber M, Ritter M, et al. Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists. *Eur Heart J*. 2008;29:71–8. [DOI] [PubMed]
13. Delise P, Sitta N, Berton G. Does long-lasting sports practice increase the risk of atrial fibrillation in healthy middle-aged men? Weak suggestions, no objective evidence. *J Cardiovasc Med (Hagerstown)*. 2012;13:381–5. [DOI] [PubMed]
14. Pelliccia A, Maron BJ, Paolo FMD, Biffi A, Quattrini FM, Pisicchio C, et al. Prevalence and clinical significance of left atrial remodeling in competitive athletes. *J Am Coll Cardiol*. 2005;46:690–6. [DOI] [PubMed]
15. Albrecht M, Koolhaas CM, Schoufour JD, Rooij FJv, Kavousi M, Ikram MA, et al. Physical activity types and atrial fibrillation risk in the middle-aged and elderly: The Rotterdam Study. *Eur J Prev Cardiol*. 2018;25:1316–23. [DOI] [PubMed] [PMC]
16. Huxley RR, Misialek JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY, et al. Physical activity, obesity, weight change, and risk of atrial fibrillation: the Atherosclerosis Risk in Communities study. *Circ Arrhythm Electrophysiol*. 2014;7:620–5. [DOI] [PubMed] [PMC]
17. Aizer A, Gaziano JM, Cook NR, Manson JE, Buring JE, Albert CM. Relation of vigorous exercise to risk of atrial fibrillation. *Am J Cardiol*. 2009;103:1572–7. [DOI] [PubMed] [PMC]

18. Calvo N, Ramos P, Montserrat S, Guasch E, Coll-Vinent B, Domenech M, et al. Emerging risk factors and the dose-response relationship between physical activity and lone atrial fibrillation: a prospective case-control study. *Europace*. 2016;18:57–63. [DOI] [PubMed] [PMC]
19. Andersen K, Rasmussen F, Held C, Neovius M, Tynelius P, Sundström J. Exercise capacity and muscle strength and risk of vascular disease and arrhythmia in 1.1 million young Swedish men: cohort study. *BMJ*. 2015;351:h4543. [DOI] [PubMed] [PMC]
20. Newman W, Parry-Williams G, Wiles J, Edwards J, Hulbert S, Kipourou K, et al. Risk of atrial fibrillation in athletes: a systematic review and meta-analysis. *Br J Sports Med*. 2021;55:1233–38. [DOI] [PubMed]
21. Ayinde H, Schweizer ML, Crabb V, Ayinde A, Abugroun A, Hopson J. Age modifies the risk of atrial fibrillation among athletes: A systematic literature review and meta-analysis. *Int J Cardiol Heart Vasc*. 2018;18:25–9. [DOI] [PubMed] [PMC]
22. Thelle DS, Selmer R, Gjesdal K, Sakshaug S, Jugessur A, Graff-Iversen S, et al. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309,540 men and women. *Heart*. 2013;99:1755–60. [DOI] [PubMed]
23. Elliott AD, Linz D, Mishima R, Kadhim K, Gallagher C, Middeldorp ME, et al. Association between physical activity and risk of incident arrhythmias in 402 406 individuals: evidence from the UK Biobank cohort. *Eur Heart J*. 2020;41:1479–86. [DOI] [PubMed]
24. Mohanty S, Mohanty P, Tamaki M, Natale V, Gianni C, Trivedi C, et al. Differential Association of Exercise Intensity With Risk of Atrial Fibrillation in Men and Women: Evidence from a Meta-Analysis. *J Cardiovasc Electrophysiol*. 2016;27:1021–9. [DOI] [PubMed]
25. Kunutsor SK, Seidu S, Mäkitallio TH, Dey RS, Laukkanen JA. Physical activity and risk of atrial fibrillation in the general population: meta-analysis of 23 cohort studies involving about 2 million participants. *Eur J Epidemiol*. 2021;36:259–74. [DOI] [PubMed] [PMC]
26. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J*. ;42:373–498. Erratum in: *Eur Heart J*. 2021;42:507. [DOI] [PubMed]
27. Lampert R, Chung EH, Ackerman MJ, Arroyo AR, Darden D, Deo R, et al. 2024 HRS expert consensus statement on arrhythmias in the athlete: Evaluation, treatment, and return to play. *Heart Rhythm*. 2024;21:e151–252. [DOI] [PubMed]
28. Iwasaki Y, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: implications for management. *Circulation*. 2011;124:2264–74. [DOI] [PubMed]
29. Farré J, Wellens HJ. Philippe Coumel: a founding father of modern arrhythmology. *Europace*. 2004;6: 464–5. [DOI] [PubMed]
30. Arbab-Zadeh A, Perhonen M, Howden E, Peshock RM, Zhang R, Adams-Huet B, et al. Cardiac remodeling in response to 1 year of intensive endurance training. *Circulation*. 2014;130:2152–61. [DOI] [PubMed] [PMC]
31. Sharma S, Merghani A, Mont L. Exercise and the heart: the good, the bad, and the ugly. *Eur Heart J*. 2015;36:1445–53. [DOI] [PubMed]
32. Bhella PS, Hastings JL, Fujimoto N, Shibata S, Carrick-Ranson G, Palmer MD, et al. Impact of lifelong exercise “dose” on left ventricular compliance and distensibility. *J Am Coll Cardiol*. 2014;64:1257–66. [DOI] [PubMed] [PMC]
33. Estes NAM 3rd, Madias C. Atrial Fibrillation in Athletes: A Lesson in the Virtue of Moderation. *JACC Clin Electrophysiol*. 2017;3:921–8. [DOI] [PubMed]

34. Afzal M, Greco F, Quinzi F, Scionti F, Maurotti S, Montalcini T, et al. The Effect of Physical Activity/Exercise on miRNA Expression and Function in Non-Communicable Diseases-A Systematic Review. *Int J Mol Sci.* 2024;25:6813. [DOI] [PubMed] [PMC]
35. Saliminejad K, Khorshid HRK, Fard SS, Ghaffari SH. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. *J Cell Physiol.* 2019;234:5451–65. [DOI] [PubMed]
36. Jiménez-Avalos JA, Fernández-Macías JC, González-Palomo AK. Circulating exosomal MicroRNAs: New non-invasive biomarkers of non-communicable disease. *Mol Biol Rep.* 2021;48:961–7. [DOI] [PubMed]
37. Reed A, Kohl P, Peyronnet R. Molecular candidates for cardiac stretch-activated ion channels. *Glob Cardiol Sci Pract.* 2014;2014:9–25. [DOI] [PubMed] [PMC]
38. Peyronnet R, Nerbonne JM, Kohl P. Cardiac Mechano-Gated Ion Channels and Arrhythmias. *Circ Res.* 2016;118:311–29. [DOI] [PubMed] [PMC]
39. Fatkin D, Cox CD, Huttner IG, Martinac B. Is There a Role for Genes in Exercise-Induced Atrial Cardiomyopathy? *Heart Lung Circ.* 2018;27:1093–8. [DOI] [PubMed]
40. Lasocka Z, Lewicka-Potocka Z, Faran A, Daniłowicz-Szymanowicz L, Nowak R, Kaufmann D, et al. Exercise-Induced Atrial Remodeling in Female Amateur Marathon Runners Assessed by Three-Dimensional and Speckle Tracking Echocardiography. *Front Physiol.* 2022;13:863217. [DOI] [PubMed] [PMC]
41. Petrongaro M, Fusco L, Cavarretta E, Scarà A, Borrelli A, Romano S, et al. Long-Term Sports Practice and Atrial Fibrillation: An Updated Review of a Complex Relationship. *J Cardiovasc Dev Dis.* 2023;10:218. [DOI] [PubMed] [PMC]
42. Gelder ICV, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J.* 2024;45:3314–414. [DOI] [PubMed]
43. Furlanello F, Bertoldi A, Dallago M, Galassi A, Fernando F, Biffi A, et al. Atrial fibrillation in elite athletes. *J Cardiovasc Electrophysiol.* 1998;9:S63–8. [PubMed]
44. Hoogsteen J, Schep G, Hemel NMV, Wall EEVD. Paroxysmal atrial fibrillation in male endurance athletes. A 9-year follow up. *Europace.* 2004;6:222–8. [DOI] [PubMed]
45. Apelland T, Janssens K, Loennechen JP, Claessen G, Sørensen E, Mitchell A, et al. Effects of training adaption in endurance athletes with atrial fibrillation: protocol for a multicentre randomised controlled trial. *BMJ Open Sport Exerc Med.* 2023;9:e001541. [DOI] [PubMed] [PMC]
46. Wilhelm M. Atrial fibrillation in endurance athletes. *Eur J Prev Cardiol.* 2014;21:1040–8. [DOI] [PubMed]
47. Furlanello F, Lupo P, Pittalis M, Foresti S, Vitali-Serdoz L, Francia P, et al. Radiofrequency catheter ablation of atrial fibrillation in athletes referred for disabling symptoms preventing usual training schedule and sport competition. *J Cardiovasc Electrophysiol.* 2008;19:457–62. [DOI] [PubMed]
48. Sanna GD, Gabrielli E, Vito ED, Nusdeo G, Prisco D, Parodi G. Atrial fibrillation in athletes: From epidemiology to treatment in the novel oral anticoagulants era. *J Cardiol.* 2018;72:269–76. [DOI] [PubMed]
49. Myrstad M, Aarønæs M, Graff-Iversen S, Ariansen I, Nystad W, Ranhoff AH. Physical activity, symptoms, medication and subjective health among veteran endurance athletes with atrial fibrillation. *Clin Res Cardiol.* 2016;105:154–61. [DOI] [PubMed]
50. Tatangelo M, Rebecchi M, Sgueglia M, Colella A, Crescenzi C, Panattoni G, et al. The Complex but Fascinating Relationship between Sport and Atrial Fibrillation: From Pathophysiology to the Clinical Scenario. *J Cardiovasc Dev Dis.* 2023;10:255. [DOI] [PubMed] [PMC]
51. Minardi S, Sciarra L, Robles AG, Scara A, Sciarra F, Luca GDMD, et al. Thromboembolic prevention in athletes: management of anticoagulation in sports players affected by atrial fibrillation. *Front Pharmacol.* 2024;15:1384213. [DOI] [PubMed] [PMC]

52. Zeppilli P, Biffi A, Cammarano M, Castelletti S, Cavarretta E, Cecchi F, et al. Italian Cardiological Guidelines (COCIS) for Competitive Sport Eligibility in athletes with heart disease: update 2024. *Minerva Med.* 2024;115:533–64. [DOI] [PubMed]
53. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al.; ESC Scientific Document Group. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. *Eur Heart J.* 2021;42:17–96. [DOI] [PubMed]